Journal Mobile Options
Table of Contents
Vol. 129, No. 3, 2013
Issue release date: April 2013
Acta Haematol 2013;129:187–196

Simultaneous and Sequential Concurrent Myeloproliferative and Lymphoproliferative Neoplasms

Hauck G. · Jonigk D. · Kreipe H. · Hussein K.
Institute of Pathology, Hannover Medical School, Hannover, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Concurrent manifestation of two chronic-stage myeloid and lymphoid/plasmacytoid neoplasms in one patient is rare and occurs in ≤1% of patients. There has been no systematic analysis of which combinations are frequent/infrequent and whether two concurrent diseases in one patient are clonally related or represent independent diseases. We therefore characterised a series of cases from our own archive (n = 65) and collected a large number of previously reported cases of patients in whom myeloid and lymphoid/plasmacytoid neoplasms co-occurred (n = 185). The most frequent combination was Philadelphia chromosome-negative myeloproliferative neoplasm with concurrent B cell chronic lymphocytic leukaemia, accounting for approximately 50% of double-disease patients. We compared the quantity of unsorted bone marrow cell-derived JAK2V617F and KITD816V alleles with the quantity of the lymphoid/plasmacytoid compartment and analysed a subfraction of cases with fluorescence in situ hybridisation. Although a common aberrant progenitor has been reported in some cases in the literature, we found evidence of two independent chronic-stage myeloid and lymphoid/plasmacytoid neoplasms.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Royle JA, Baade PD, Joske D, Girschik J, Fritschi L: Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011;105:1076–1081.
  2. Bhatia R, Deeg HJ: Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol 2011;18:77–82.
  3. George TI, Horny HP: Systemic mastocytosis. Hematol Oncol Clin North Am 2011;25:1067–1083, vii.
  4. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP: Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010;220:586–595.
  5. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A, Lauria F: Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007;8:864–866.
  6. Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Büsche G, Kreipe H: Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008;22:1059–1062.
  7. Hussein K, Horny HP, Büsche G, Görner M, Göhring G, Kreipe H, Bock O: Systemic mastocytosis (SM) with associated BCR-ABL-positive myelogenous leukaemia (SMAHNMD): evidence that mast cells do not belong to the leukaemic clone. Leukemia 2011;25:1050–1053.
  8. Oka K, Nagayama R, Yonekawa N, Nihei T, Sando N, Yatabe Y, Mori N: Concurrent gastric MALT and Hodgkin lymphoma: a case report. Int J Surg Pathol 2012;20:201–204.
  9. Camós M, Cervantes F, Montoto S, Hernández-Boluda JC, Villamor N, Montserrat E: Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma 1999;32:395–398.
  10. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES: Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol 2011;24:1421–1432.
  11. Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D’Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, Tedeschi A, Ambrosetti A, Gaidano G, Leone G, Foà R: The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol 2011;86:1007–1012.
  12. Florensa L, Vallespí T, Woessner S, Domingo A, Crespo N, Rozman M, Aguilar JL, Irriguible D, Zarco A, Millá F, Feliu E: Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma 1996;23:609–612.
  13. Hussein K, Brakensiek K, Ballmaier M, Bormann M, Göhring G, Buhr T, Bock O, Kreipe H: B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006;77:539–541.
  14. Kremer M, Horn T, Koch I, Dechow T, Gattenloehner S, Pfeiffer W, Quintanilla-Martínez L, Fend F: Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 2008;32:928–935.
  15. Kodali S, Chen C, Rathnasabapathy C, Wang JC: JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res 2009;33:e236–e239.
  16. Musolino C, Allegra A, Penna G, Centorrino R, Cuzzola M, D’Angelo A, Iacopino P, Alonci A: Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol 2009;122:46–49.
  17. Abeliovich D, Yehuda O, Ben-Neriah S, Matzner Y: Therapy-related myelodysplastic syndrome. Two cytogenetically unrelated abnormal clones in a patient with multiple myeloma. Cancer Genet Cytogenet 1993;70:117–119.
  18. Acar H, Ecirli S, Gündoğan F, Bulay O, Acar A: Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis. Cancer Genet Cytogenet 1999;108:171–174.
  19. Arlen PM, Goldkland GA: Multiple myeloma after treatment of essential thrombocythemia. South Med J 1995;88:79–81.
  20. Aviv H, Tang D, Das K, Harrison JS, Hameed M, Varma M: Simultaneous appearance of trisomy 8 and trisomy 12 in different cell populations in a patient with untreated B-cell chronic lymphocytic leukemia and myelodysplasia. Leuk Lymphoma 2004;45:1279–1283.
  21. Au WY, Ma SK, Wan TS, Wang EP, Lau TC, Kwong YL: Concurrent mediastinal B cell lymphoma and chronic myeloid leukemia with an unusually favorable response to chemotherapy. Leuk Lymphoma 2003;44:535–538.
  22. Botelho de Sousa A, Gouveia J: Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment. Med Oncol Tumor Pharmacother 1989;6:239–240.
  23. Bosch F, Cervantes F, Lopez-Guillermo A, Carreras E, Montserrat E, Rozman C: Polycythaemia vera following non-Hodgkin’s lymphoma. Leuk Lymphoma 1992;8:501–502.
  24. Breccia M, Petti MC, D’Elia GM, D’Andrea M, Carmosino I, Alimena G: Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. Eur J Haematol 2002;68:1–3.
  25. Callea V, Brugiatelli M, Stelitano C, Gentile M, Nobile F, Morabito F: Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma 2006;47:2314–2320.
  26. Carulli G, Marini A, Baicchi U, Simi P, Papineschi F, Ambrogi F: Chronic lymphocytic leukemia (B-cell) in the course of polycythemia vera. Description of a case with an unusual chromosomic anomaly. Tumori 1987;73:639–643.
  27. Cobo F, Cervantes F, Martinez C, Salgado C, Blade J, Montserrat E, Rozman C: Multiple myeloma following essential thrombocythemia. Leuk Lymphoma 1995;20:177–179.
  28. Cottrill C, Geller A, diSpaltro FX, Weissglass B, Klainer AS, Bisaccia E: Control of polycythaemia vera with photochemotherapy in a patient with cutaneous T-cell lymphoma. Br J Haematol 1994;86:225–226.
  29. Economopoulos T, Pappa V, Panani A, Stathakis N, Dervenoulas J, Papageorgiou E, Asprou N, Raptis S: Myelopathies during the course of multiple myeloma. Haematologica 1991;76:289–292.
  30. Fink L, Bauer F, Perry JJ: Coincidental polycythemia vera and multiple myeloma: case report and review. Am J Hematol 1993;44:196–200.
  31. Fukuda N, Shinohara K, Ota I, Muraki K, Shimohakamada Y: Therapy-related myelodysplastic syndrome in a case of cutaneous adult T-cell lymphoma. Int J Hematol 2002;75:67–71.
  32. Gabrail NY, Martin TW: Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematol 1991;85:31–33.
  33. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G: Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349–353.
  34. Harrison P, Neilson JR, Lumley MA, Milligan DW: Development of polycythaemia rubra vera following treatment for centroblastic lymphoma. Acta Haematol 1996;96:113–114.
  35. Hauswirth AW, Födinger M, Fritz M, Müllauer L, Simonitsch-Klupp I, Streubel B, Chott A, Sperr WR, Jäger U, Valent P: Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Hum Pathol 2008;39:917–924.
  36. Horny HP, Sotlar K, Stellmacher F, Valent P, Grabbe J: An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 2006;59:264–268.
  37. Horny HP, Sotlar K, Valent P: Mastocytosis: state of the art. Pathobiology 2007;74:121–132.
  38. Huang HH, Zhu JY, Han JY, Shen LJ, Xu L, Chen XL, Zheng LY, Chen FY: Co-existent de novo myelodysplastic syndrome and T-cell non-Hodgkin lymphoma: a common origin or not? J Int Med Res 2009;37:270–276.
  39. Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, Griffin JD, Kadin ME, Ooya K: Ph-negative non-Hodgkin’s lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia 2000;14:169–182.
  40. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J: MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003;122:430–440.
  41. Jacobsen N, Theilade K, Videbaek A: Two additional cases of coexisting polycythaemia vera and chronic lymphocytic leukaemia. Scand J Haematol 1982;29:405–410.
  42. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
  43. Januszewicz E, Firkin FC: Dual presentation of polycythaemia vera and lymphatic leukaemia. Aust NZ J Med 1980;10:209–211.
  44. Kelsey PR, Patel K: Essential thrombocythaemia followed by multiple myeloma in the same patient. Clin Lab Haematol 1995;17:349–351.
  45. Kim Y, Weiss LM, Chen YY, Pullarkat V: Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res 2007;31:1749–1754.
  46. Kobayashi Y, Nakayama M, Uemura N, Takeyama K, Tobinai K, Takenaka T, Choi SH, Satoh H, Mori S, Asano S: Analysis of myelodysplastic syndrome clones arising after multiple myeloma: a case study by correlative interphase cytogenetic analysis. Jpn J Clin Oncol 1999;29:374–377.
  47. Koza I, Babusikova O: Sequential development of chronic lymphocytic leukemia in a patient with polycythemia vera. Neoplasma 1988;35:77–80.
  48. Kuroda J, Matsumoto Y, Tanaka R, Kurita K, Kobayashi T, Shimizu D, Kimura S, Ashihara E, Horiike S, Shimazaki C, Taniwaki M: JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones. Acta Haematol 2008;120:177–181.
  49. Lai R, Arber DA, Brynes RK, Chan O, Chang KL: Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Am J Clin Pathol 1999;111:373–378.
  50. Liu ML, Kallakury B, Kessler C, Hartmann DP, Azumi N, Ozdemirli M: Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma. Leuk Lymphoma 2006;47:315–322.
  51. Massa FS, Rolón JM, Pavlovsky S: Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin’s lymphoma who underwent autologous hematopoietic stem cell transplantation. Hematology 2007;12:487–488.
  52. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB: Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573–4575.
  53. Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I: Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis. Ann Hematol 1997;74:193–197.
  54. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878–3884.
  55. Mossafa H, Fourcade C, Pulic M, Jary L, Cheze S, Szpiro-Tapia S, Troussard X: Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma 2001;41:337–341.
  56. Nieto LH, Raya Sánchez JM, Arguelles HA, Brito Barroso ML, González BG: A case of chronic lymphocytic leukemia overwhelmed by rapidly progressive idiopathic myelofibrosis. Haematologica 2000;85:973–977.
  57. Nilsson T, Nilsson L, Lenhoff S, Rylander L, Astrand-Grundström I, Strömbeck B, Höglund M, Turesson I, Westin J, Mitelman F, Jacobsen SE, Johansson B: MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004;41:223–231.
  58. Orciuolo E, Fazzi R, Galimberti S, Testi C, Azzara’ A, Carulli G, Petrini M: Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy. Leuk Res 2006;30:349–353.
  59. Pajor L, Kereskai L, Tamaska P, Vass JA, Radvanyi G: Coexistence of chronic myeloid leukemia and hairy cell leukemia of common clonal origin. Cancer Genet Cytogenet 2002;134:114–117.
  60. Papayannis AG, Nikiforakis E, Aanagnostou-Keramida D: Development of chronic lymphocytic leukaemia in a patient with polycythaemia vera. Scand J Haematol 1982;29:65–69.
  61. Park TS, Cheong JW, Song J, Choi JR: Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res 2009;33:1001–1004.
  62. Polkowska-Kulesza E, Matusewicz W, Golebiowska A, Najder M, Urbanska-Rys H, Jodlowska E: The coexistence of chronic lymphocytic leukaemia and polycythaemia vera terminating in acute myeloid leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:647–652.
  63. Prósper F, Borbolla JR, Rifón J, Cuesta B, Fernández J, Pinacho A, Rocha E: Coexistence of essential thrombocythemia and multiple myeloma. Ann Hematol 1992;65:103–105.
  64. Przepiorka D, Buadi F, McClune B, Franz G, Walsh W, White F: Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2007;40:759–764.
  65. Pulsoni A, Bianco P, La Verde G, Mecarocci S, Petrucci MT, Torromeo C, Avvisati G: Coexistent multiple myeloma and myelofibrosis. Leuk Lymphoma 1993;10:401–403.
  66. Robak T, Urbańska-Ryś H, Góra-Tybor J, Wawrzyniak E, Korycka A, Bartkowiak J, Kordek R, Polliack A: Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma 2003;44:1425–1431.
  67. Robertson LE, Estey E, Kantarjian H, Koller C, O’Brien S, Brown B, Keating MJ: Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 1994;8:2047–2051.
  68. Rizzi R, Liso A, Pannunzio A, Carluccio P, Specchia G, Liso V: Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature. Leuk Lymphoma 2002;43:2217–2220.
  69. Saba NF, Warth JA, Ross DG: Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature. Haematologia (Budap) 2002;32:17–23.
  70. Saletti P, Ghielmini M, Scali G, Pedrinis E, Guéneau M, Cavalli F: Hodgkin’s and Castleman’s disease in a patient with systemic mastocytosis. Ann Hematol 1999;78:97–100.
  71. Schlaifer D, Dastugue N, Brousset P, Delsol G, Muller C, Rigal-Huguet F, Attal M, Laurent G, Pris J: B-cell lymphoma following polycythemia vera: evidence for the involvement of two different clones. Leukemia 1994;8:895–896.
  72. Schmetzer HM, Mittermüller J, Duell T, Wilmanns W: Development of myeloma and secondary myelodysplastic syndrome from a common clone. Cancer Genet Cytogenet 1998;100:31–35.
  73. Sever M, Jorgensen JL, Gurevich I, Pinheiro M, Verstovsek S: Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. Leuk Res 2009;33):e186–e188.
  74. Shibata K, Shimamoto Y, Nakazato S, Matsuzaki M, Tadano J: Refractory anaemia with ringed sideroblasts concurrent with multiple myeloma – a brief review of the recent literature. Haematologia (Budap) 1997;28:199–205.
  75. Soenen V, Preudhomme C, Roumier C, Laï JL, Lepelley P, Facon T, Pagniez D, Fenaux P: Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. Leukemia 1998;12:238–241.
  76. Steinmetz C, Shabaik A, Hasteh F: Systemic mastocytosis associated with small lymphocytic lymphoma: an incidental finding in a patient with invasive gastric adenocarcinoma. Diagn Cytopathol 2007;35:728–733.
  77. Tanaka M, Kimura R, Matsutani A, Zaitsu K, Oka Y, Oizumi K: Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature. Acta Haematol 1998;99:221–223.
  78. Terpstra WE, Meuwissen OJ, Hagemeijer A, Michiels JJ: Multiple myeloma and acute megakaryoblast leukemia in spent phase polycythemia vera. Am J Clin Pathol 1990;94:786–790.
  79. Tsiara S, Economou G, Panteli A, Isaakidis P, Kapsali E, Bourantas KL: Coexistence of myelodysplastic syndrome and multiple myeloma. J Exp Clin Cancer Res 1999;18:565–566.
  80. Ueki K, Sato S, Tamura J, Sawamura M, Murakami H, Naruse T, Tsuchiya J: Three cases of multiple myeloma developing into melphalan-related chronic myelomonocytic leukemia. J Med 1991;22:157–161.
  81. Yağci M, Sucak GT, Oğur G, Haznedar R: Therapy-related refractory anemia with ringed sideroblasts in chronic lymphocytic leukemia. Involvement of 3q21 region. Cancer Genet Cytogenet 2001;129:43–46.
  82. Zámecníková A, Vranovský A, Hlavcák P: Coexistence of Philadelphia-positive chronic granulocytic leukemia and diffuse large B-cell lymphoma at initial diagnosis. Leuk Lymphoma 2002;43:429–431.
  83. Cehreli C, Undar B, Akkoc N, Onvural B, Altungoz O: Coexistence of chronic neutrophilic leukemia with light chain myeloma. Acta Haematol 1994;91:32–34.
  84. Dinçol G, Nalçaci M, Doğan O, Aktan M, Küçükkaya R, Ağan M, Dinçol K: Coexistence of chronic neutrophilic leukemia with multiple myeloma. Leuk Lymphoma 2002;43:649–651.
  85. Franchi F, Seminara P, Giunchi G: Chronic neutrophilic leukemia and myeloma. Report on long survival. Tumori 1984;70:105–107.
  86. Ito K, Usuki K, Iki S, Urabe A: Chronic neutrophilic leukemia associated with chronic lymphocytic leukemia. Int J Hematol 1998;68:87–94.
  87. Lewis MJ, Oelbaum MH, Coleman M, Allen S: An association between chronic neutrophilic leukaemia and multiple myeloma with a study of cobalamin-binding proteins. Br J Haematol 1986;63:173–180.
  88. Rovira M, Cervantes F, Nomdedeu B, Rozman C: Chronic neutrophilic leukaemia preceding for seven years the development of multiple myeloma. Acta Haematol 1990;83:94–95.
  89. Standen GR, Steers FJ, Jones L: Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta. J Clin Pathol 1993;46:297–298.
  90. Standen GR, Jasani B, Wagstaff M, Wardrop CA: Chronic neutrophilic leukemia and multiple myeloma. An association with lambda light chain expression. Cancer 1990;66:162–166.
  91. Zoumbos NC, Chrysanthopoulos C, Starakis J, Kapatais-Zoumbos K: Kappa light chain myeloma developing in a patient with chronic neutrophilic leukaemia. Br J Haematol 1987;65:504–505.
  92. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H: JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186–1193.e7.
  93. Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kröger N, Göhring G, Büsche G, Kreipe H: Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood 2009;113:1391–1392.
  94. Ishii T, Bruno E, Hoffman R, Xu M: Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128–3134.
  95. Takahashi N, Miura I, Saitoh K, Miura AB: Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998;92:4758–4763.
  96. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA: Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992;81:346–352.
  97. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D: The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005;131:320–318.
  98. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R: The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009;113:5246–5249.
  99. Gattenlohner S, Ertl G, Einsele H, Kircher S, Muller-Hermelink HK, Marx A: Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease. Ann Intern Med 2008;149:69–71.
  100. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377–3379.
  101. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH: JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 2006;47:313–314.
  102. Wang YL, Lee JW, Kui JS, Chadburn A, Cross NC, Knowles DM, Coleman M: Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematol 2007;118:209–214.
  103. Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A: Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007;35:1668–1676.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50